24 results on '"coronary artery ectasia (CAE)"'
Search Results
2. Frequency of coronary artery ectasia in patients with myocardial infarction.
- Author
-
Nazim, Muhammad, Ali, Sajid, Asghar, Naeem, Maqbool, Abubakar, and Ilyas, Rana Faiq
- Subjects
- *
CORONARY arteries , *MYOCARDIAL infarction , *CARDIAC patients , *CORONARY angiography , *FILM reviewing - Abstract
Objective: To determine the frequency of coronary artery ectasia in patients with MI in our population. Study Design: Descriptive, Cross Sectional study. Setting: Cardiac Catheterization Department of Ch. Pervaiz Elahi Institute of Cardiology, Multan. Period: 1st October 2019 to 31st March 2020. Material & Methods: A total of 191 patients with myocardial infarction of age 18-60 years of either gender undergoing coronary angiography were included. Patients with vulvular heart disease, cardiomyopthies, heart failure and CKD were excluded. Full demographic informations including name, age, gender and risk factors like diabetes mellitus (DM), hypertension (HTN) and smoking were noted. The coronary angiographic films were reviewed and looked for presence or absence of coronary artery ectasia. Results: Mean age was 49.28 ± 9.64 years in our study. Out of the 191 patients, 85.86% were male and 14.14% were females with ratio of 6:1. The %age of vessel involvement in descending order was right coronary artery in 56.02%, left anterior descending artery in 25.13%, left circumflex artery in 13.10% and left main stem in 5.76% patients. Coronary artery ectasia was found in 62.83% patients. Conclusion: This study concluded that there is a high frequency of coronary artery ectasia (CAE) in myocardial infarction patients with positive association with older age, male gender, hypertension, diabetes mellitus and smoking. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Editorial: Lipid metabolism and human diseases
- Author
-
Peter U. Amadi, Hong-Mei Gu, Kai Yin, Xian-Cheng Jiang, and Da-wei Zhang
- Subjects
low-density lipoprotein (LDL) ,metabolic-associated fatty liver disease ,coronary artery ectasia ,idiopathic pulmonary fibrosis (IDF) ,coronary artery ectasia (CAE) ,atherosclerotic cardiovascular disease (ASCVD) ,Physiology ,QP1-981 - Published
- 2022
- Full Text
- View/download PDF
4. Five-years’ prognostic analysis for coronary artery ectasia patients with coronary atherosclerosis: A retrospective cohort study
- Author
-
Ruifeng Liu, Xiangyu Gao, Siwen Liang, and Huiqiang Zhao
- Subjects
coronary artery ectasia (CAE) ,coronary heart disease (CHD) ,acute myocardial infarction (AMI) ,major cardiovascular events (MACE) ,prognosis ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
BackgroundMost of coronary artery ectasia (CAE) patients have comorbid coronary atherosclerosis. It was lack of prognostic data for CAE patients with coronary heart disease (CHD) and for whom with acute myocardial infarction (AMI).ObjectiveTo determine the overall prognosis for CAE patients.Materials and methodsThis study was a retrospective cohort study. Fifty-one patients with CAE and comorbid AMI (CAE + AMI) and 108 patients with CAE and comorbid CHD (CAE + CHD) were enrolled and matched to non-CAE subjects at a ratio of 1:3 using a propensity score method, respectively. Controls for CAE + AMI group were 153 AMI patients, controls for CAE group were 324 CHD patients and 329 participants with relatively normal coronary arteries (CON). We followed them up to observe major cardiovascular events (MACE).ResultsThe Kaplan-Meier curves showed that the prognosis in CAE + AMI group was worse than in AMI group (5-year non-MACE rate: 62.70% vs. 79.70%, P = 0.010), the prognosis in CAE group was worse than in CHD and CON groups (5-year non-MACE rate: 74.10% vs. 85.80% and 96.70%, respectively, P = 0.000). The main MACEs in CAE + AMI and CAE groups were AMI reoccurrence (19.61% vs. 4.57%, P = 0.002) and re-hospitalization due to repeated angina pectoris (14.81% vs. 8.33% and 2.74%, P = 0.000), respectively. Additionally, the COX regression analysis revealed that the protective factors for preventing MACE in CAE + AMI group included antiplatelet agents (hazard ratio = 0.234, P = 0.016) and angiotensin-converting enzyme inhibitor/angiotensin receptor inhibitor (ACEI/ARB, hazard ratio = 0.317, P = 0.037). Whereas the main factor promoting MACE in CAE group was the degree of coronary stenosis (Gensini score, hazard ratio = 1.011, P = 0.022).ConclusionThe prognosis of patients with CAE + AMI was worse than that of those with AMI. The overall prognosis of patients with CAE was worse than that of those with CHD. CAE + AMI and CAE groups had different characteristics; the former was prone to AMI reoccurrence, and the latter was prone to repeated angina pectoris. To prevent MACE, medications, including antiplatelets and ACEI/ARBs, are indicated for patients with CAE + AMI, whereas prevention of the progression of atherosclerotic lesions is indicated for patients with CAE.
- Published
- 2022
- Full Text
- View/download PDF
5. Receptor for advanced glycation end products polymorphisms in coronary artery ectasia.
- Author
-
Aslan, Ezgi Irmak, Ozkara, Gulcin, Kilicarslan, Onur, Ser, Ozgur Selim, Bostan, Cem, Yildiz, Ahmet, Diren Borekcioglu, Ayca, Ozturk, Oguz, Kucukhuseyin, Ozlem, and Yilmaz Aydogan, Hulya
- Subjects
- *
ADVANCED glycation end-products , *RECEPTOR for advanced glycation end products (RAGE) , *CORONARY arteries , *LOGISTIC regression analysis , *CORONARY artery disease , *CORONARY angiography - Abstract
[Display omitted] • The RAGE -374 AA genotype and A allele significantly increases the risk of CAE. • In controls without systemic disease, -374A allele was associated with low sRAGE levels. • In CAEs receiving antihypertensive and antidiabetic treatment, sRAGE levels were increased. • Antihypertensive treatment may contribute to the CAE prognosis by increasing sRAGE. • The -374A allele is also associated with younger patient age and higher platelet count in CAE. Although the implication of receptor of advanced glycation endproducts (RAGE) has been reported in coronary artery disease, its roles in coronary artery ectasia (CAE) have remained undetermined. Furthermore, the effect of RAGE polymorfisms were not well-defined in scope of soluble RAGE (sRAGE) levels. Thus, we aimed to investigate the influence of the functional polymorphisms of RAGE -374T > A (rs1800624) and G82S (rs2070600) in CAE development. This prospective observational study was conducted in 2 groups selected of 2452 patients who underwent elective coronary angiography (CAG) for evaluation after positive noninvasive heart tests. Group-I included 98 patients with non-obstructive coronary artery disease and CAE, and Group-II (control) included 100 patients with normal coronary arteries. SNPs were genotyped by real-time PCR using Taqman® genotyping assay. Serum sRAGE and soluble lectin-like oxidized receptor-1 (sOLR1) were assayed by ELISA and serum lipids were measured enzymatically. The frequencies of the RAGE -374A allele and -374AA genotype were significantly higher in CAE patients compared to controls (p < 0.001). sRAGE levels were not different between study groups, while sOLR1 levels were elevated in CAE (p = 0.004). In controls without systemic disease, -374A allele was associated with low sRAGE levels (p < 0.05), but this association was not significant in controls with HT. Similarly, sRAGE levels of CAE patients with both HT and T2DM were higher than those no systemic disease (p = 0.02). The -374A allele was also associated with younger patient age and higher platelet count in the CAE group in both total and subgroup analyses. In the correlation analyses, the -374A allele was also negatively correlated with age and positively correlated with Plt in all of these CAE groups. In the total CAE group, sRAGE levels also showed a positive correlation with age and a negative correlation with HDL-cholesterol levels. On the other hand, a negative correlation was observed between sRAGE and Plt in the total, hypertensive and no systemic disease control subgroups. Multivariate logistic regression analysis confirmed that the -374A allele (p < 0.001), hyperlipidemia (p < 0.05), and high sOLR1 level (p < 0.05) are risk factors for CAE. ROC curve analysis shows that RAGE -374A allele has AUC of 0.713 (sensitivity: 83.7 %, specificity: 59.0 %), which is higher than HLD (sensitivity: 59.2 %, specificity: 69.0 %), HT (sensitivity: 62.4 %, specificity: 61.1 %) and high sOLR1 level (≥0.67 ng/ml)) (sensitivity: 59.8 %, specificity: 58.5 %). Beside the demonstration of the relationship between -374A allele and increased risk of CAE for the first time, our results indicate that antihypertensive and antidiabetic treatment in CAE patients causes an increase in sRAGE levels. The lack of an association between the expected -374A allele and low sRAGE levels in total CAE group was attributed to the high proportion of hypertensive patients and hence to antihypertensive treatment. Moreover, the RAGE -374A allele is associated with younger age at CAE and higher Plt, suggesting that -374A may also be associated with platelet activation, which plays a role in the pathogenesis of CAE. However, our data need to be confirmed in a large study for definitive conclusions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Chronic active Epstein–Barr virus infection manifesting as coronary artery aneurysm and uveitis
- Author
-
Haijuan Xiao, Bing Hu, Rongmu Luo, Huili Hu, Junmei Zhang, Weiying Kuang, Rui Zhang, Li Li, and Gang Liu
- Subjects
Chronic active Epstein–Barr virus infection (CAEBV) ,Coronary artery aneurysm (CAA) ,Coronary artery ectasia (CAE) ,Lymphoproliferative disorders (LPDs) ,Uveitis ,Hematopoietic stem cell transplantation (HSCT) ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Chronic active Epstein–Barr virus (CAEBV) infection is a type of lymphoproliferative disorder characterized by chronic or recurrent infectious mononucleosis (IM)-like symptoms, which can have less-frequent clinical presentations. The prognosis of CAEBV is poor, and hematopoietic stem cell transplantation (HSCT) has been shown to be the only potentially effective treatment. In this article, we present a special CAEBV case of a patient who had no typical IM-like symptoms at the early stage, but manifested with severe and progressive coronary artery aneurysm (CAA), abdominal aortic lesions, and severe uveitis. These manifestations were uncommon features and could only be blocked by HSCT. Case presentation A 4-year-old girl with no special medical history complained of decreased vision for 10 months and cough after physical activities for three months. The blurred vision grew rapidly worse within one month, until only light perception remained. She was diagnosed with uveitis and cataract, and received prednisone and ciclosporin A treatment. However, her vision did not improve. Physical examination showed slight hepatosplenomegaly. Ultrasonic cardiogram showed bilateral CAA (5.0 mm and 5.7 mm for inner diameters), and abdominal CT scan revealed a thickened aortic wall, as well as stenosis and dilation of the segmental abdominal aorta. Other significant findings were increased EBV-DNA (3.29 × 104 copies/mL) from peripheral blood, positive EBV antibodies (EBV-CA-IgG, EBV-EA-IgA, and EBV-NA-IgG), and positive EBV-encoded small RNAs found by bone marrow biopsy. Based on her clinical manifestations and evidence for EBV infection, we diagnosed CAEBV. She received allogeneic HSCT, and the cataract operation was performed after HSCT. EBV-DNA could not be detected in peripheral blood after HSCT. Her CAAs did not progress, and uveitis was well controlled. Her vision recovered gradually over the 3 years after HSCT. Conclusions We present a rare CAEBV case of a patient who suffered from uncommon and severe cardiovascular and ocular involvement that was relieved by HSCT. Therefore, early recognition and diagnosis of CAEBV are of vital importance to improve its prognosis. In summary, this atypical CAEBV case could help us recognize similar cases more easily, make the right diagnosis as early as possible, and deliver proper and timely treatment.
- Published
- 2020
- Full Text
- View/download PDF
7. Surgical Management of a Ruptured Giant Right Coronary Artery Aneurysm With Fistulization.
- Author
-
Aslam U, Kumar U, Gupta A, Iyengar N, and Khalpey Z
- Abstract
Coronary artery aneurysms (CAAs) are an uncommon condition with severe long-term consequences. We describe the surgical treatment of a right CAA that manifested as a compressive mass adjacent to the right atrium. A 60-year-old female patient presented with mid-sternal chest discomfort and a CT scan showing a 6.3cm x 5.5cm x 7cm mass along the anterior chest wall compressing the right atrium. Angiography revealed 95% proximal right coronary artery stenosis with contrast filling a giant CAA but no antegrade filling beyond the aneurysmal sac. While hospitalized, the patient experienced acute hypotension, and an urgent CT scan demonstrated interval bleeding into the pericardial sac with significant external compression of the right ventricular outflow. The patient was urgently taken to the operating room, where the right CAA was ligated at the neck and oversewn at the ostium. The patient developed a hemothorax on postoperative day 1 without a clear source of bleeding, but the remaining postoperative course was uneventful. Opportunities for surgery in patients with ruptured CAAs are rare due to the high pre-hospital mortality rate. Complex percutaneous coronary intervention is the preferred initial approach for asymptomatic CAAs, as was performed in this patient eight years prior. However, in the setting of acute tamponade, urgent operative intervention is the only viable management option. Aneurysmal rupture is an uncommon complication of CAAs that frequently leads to sudden death. This case demonstrates the successful management of an acutely ruptured CAA with urgent aneurysm ligation., Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2024, Aslam et al.)
- Published
- 2024
- Full Text
- View/download PDF
8. Editorial: Lipid metabolism and human diseases.
- Author
-
Amadi, Peter U., Hong-Mei Gu, Kai Yin, Xian-Cheng Jiang, and Da-wei Zhang
- Subjects
LIPID metabolism ,FATTY liver ,STEROL regulatory element-binding proteins ,MOLECULAR biology ,NON-alcoholic fatty liver disease ,LIQUID chromatography-mass spectrometry - Published
- 2022
- Full Text
- View/download PDF
9. Is Coronary Artery Ectasia a Progressive Disease? A Self-Controlled Retrospective Cohort Study
- Author
-
Ruifeng Liu, Huiqiang Zhao, Xiangyu Gao, and Siwen Liang
- Subjects
coronary artery ectasia (CAE) ,coronary angiogram (CAG) ,progression ,Gensini score ,atherosclerotic change ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Objective: It is essential to understand whether coronary artery ectasia (CAE) progresses over time because the patients might be under the risk of coronary rupture, and stent implant should be avoided if ectatic changes progress.Methods: A consecutive series of 99 CAE patients who had undergone coronary angiography at least twice were enrolled and followed up for 1–16 years until they received a second angiogram. Subjects were divided into two groups (1–5 vs. 5–16 years of follow-up), then the basic clinical characteristics and coronary artery images were compared over time.Results: (1) All CAE patients exhibited atherosclerosis, and a majority presented with acute myocardial infarction. Most baseline clinical characteristics were relatively stable. (2) Atherosclerosis (indicated by the distribution of stenosis in coronary vessels) and the Gensini scores progressed significantly. Ectasia extent showed minimal changes as indicated by blood vessel involvement, Markis type, coronary blood flow, ectasia diameter, and ectasia length. (3) Multilinear regression analysis revealed that the underlying factors related to stenosis evolution indicated by fold of Gensini score were: longer time interval, lower baseline Gensini score, and higher hypersensitive C-reactive protein concentration. (4) There was a relationship between the ectatic diameter and the extent of stenosis.Conclusions: For CAE patients with atherosclerosis followed for 1–16 years, there was minimal CAE progression, while the atherosclerosis progressed and the ectasia extent was related to degree of stenosis. The results indicate that prevention and treatment of atherosclerotic changes might have more clinical significance than addressing ectatic changes.
- Published
- 2021
- Full Text
- View/download PDF
10. Ranolazine as a First-Choice Anti-anginal Medication for Patients With Coronary Artery Ectasia: A Case Series.
- Author
-
Ahmed JA, Ahmed KA, and Ahmed MH
- Abstract
Coronary artery ectasia (CAE) is characterized by the abnormal dilation of coronary arteries, resulting in disturbed or slow blood flow, which causes angina pectoris-the most prevalent symptom of CAE. To date, there is no consensus on the therapeutic management of CAE due to its rarity and the scarcity of research. We present a case series of five patients with different ethnicities, including both men and women, whose CAE was successfully managed by the administration of ranolazine. All five patients were found to have CAE by coronary angiography, which was also associated with slow blood flow. Clinically, the patients had accelerating angina. They were prescribed an initial dose of 500 mg of ranolazine twice daily, which led to the resolution of their anginal symptoms. They have been clinically and hemodynamically stable for the last several years. In light of these results, we propose that ranolazine be considered as a first-choice anti-anginal medication for patients with CAE., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2024, Ahmed et al.)
- Published
- 2024
- Full Text
- View/download PDF
11. Commentary: Coronary artery mycotic aneurysm in a patient suffering from subacute endocarditis: a case report and literature review.
- Author
-
Kalhor P and Davarpasand T
- Abstract
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF
12. Extracellular matrix turnover in coronary artery ectasia patients.
- Author
-
Liu, Ruifeng, Chen, Lianfeng, Wu, Wei, Chen, Houzao, and Zhang, Shuyang
- Subjects
- *
CORONARY disease , *EXTRACELLULAR matrix , *METABOLIC disorders , *PROTEOLYTIC enzymes , *MATRIX metalloproteinases , *COLLAGEN - Abstract
Dysregulation of the metabolism of the extracellular matrix (ECM) may contribute to coronary artery ectasia (CAE). This study evaluated the turnover of main ECM components and related proteolytic enzymes activities. In this study, thirty patients with CAE, 30 patients with coronary artery disease (CAD) and 30 subjects with normal coronary arteries (Control) were selected. The following circulating ECM metabolism markers were measured: soluble elastin (sElastin), collagen type I cross-linked telopeptides (ICTP), procollagen type I carboxy terminal peptide (PICP), protocollagen III N-terminal propeptide (PIIINP), and procollagen a1(III) C-terminal propeptide (PIIICP). Serum total elastase activity and total matrix metalloproteinase (MMP) activity were also determined. The level of sElastin was higher in the CAE group than in the CAD and Control groups ( P1 = 0.009, P2 = 0.000). There was no difference in ICTP ( P = 0.168) or PIIICP ( P = 0.079) among the three groups. PICP was significantly elevated in CAE ( P1 = 0.001, P2 = 0.002). PIIINP was also significantly increased in CAE ( P1 = 0.002, P2 = 0.007). Total elastase activity was higher in the CAE group than in the other two groups ( P1 = 0.006, P2 = 0.022). Total MMP activity was significantly higher in the CAE group than the Control group ( P2 = 0.013) but not higher than the CAD group ( P1 = 0.477). In conclusion, within CAE patients the main changes in ECM metabolism were increased degradation of elastin fibres and the transition of collagen from type III to type I. Elastase and MMPs appear to be associated with this kind of ECM turnover. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
13. Transcriptional expression profiles of the main proteinases and their regulators in coronary artery ectasia patients' mononuclear cells.
- Author
-
Ruifeng LIU, Wei WU, Lianfeng CHEN, Houzao CHEN, and Shuyang ZHANG
- Abstract
Objective Proteolytic enzymes might contribute to coronary artery ectasia (CAE) through the destruction of extracellular matrix (ECM) vessel components. This study aimed to find out if peripheral blood mononuclear cells (PBMCs) served as a source of those proteinases and their regulators. Method In this study, transcriptional expression profiles of the main proteinases and their regulators were detected in the PBMCs of CAE patients as follows: (1) matrix metalloproteinases (MMP) 1, 2, 3, 8, 9, 10, 12 and 13; (2) the serine proteinases elastase: cathepsin G and proteinases 3; (3) the cysteine proteinases: cathepsin L and cathepsin S; (4) the main endogenous inhibitors for the above proteinases: tissue inhibitors of metalloproteinase (TIMP) 1 and 2, α1-antitrypsin (α1-PI) and α2-macroglobulin (A2M); (5) twelve cytokines that could regulate the above proteinases. Result The characteristic changes in CAE were: (1) MMP1 and MMP9 increased while the serine and cysteine families did not change; (2) the four proteinase inhibitors did not change in the CAE group; (3) among the 12 cytokines, interleukin-1 alpha (IL1A), platelet-derived growth factor (PDGF), interferon gamma (IFNγ) and growth differentiation factor 15 (GDF15) were elevated. Partial correlation analysis showed that MMP1 significantly correlated with IL1A and with IFNγ, and MMP9 correlated with IFNγ and with GDF 15. Conclusion PBMCs might participate in the pathological process of CAE by the increased expression of MMP1, MMP9, IL1A, IFNγ and GDF15. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
14. Neutrophil serine proteases and their endogenous inhibitors in coronary artery ectasia patients.
- Author
-
Ruifeng Liu, Lianfeng Chen, Wei Wu, Houzao Chen, and Shuyang Zhang
- Subjects
- *
NEUTROPHILS , *SERINE proteinases , *ELASTIN , *EXTRACELLULAR matrix , *PROTEOLYTIC enzymes - Abstract
Objective: Proteolytic enzymes possibly contribute to coronary artery ectasia (CAE). This study aimed to determine whether neutrophils, neutrophil serine proteases (NSPs), and their endogenous inhibitors participated in the pathological process of CAE. Methods: The study consisted of 30 patients with CAE, 30 patients with coronary artery disease (CAD), and 29 subjects with normal coronary arteries (Control). The following circulating items were measured: the main NSPs, including human neutrophil elastase (HNE), cathepsin G (CG), and proteinase 3 (PR3); soluble elastin (sElastin), which was a degradation product of elastin fibres; NSP inhibitors such as α1-protease inhibitor (α1-PI), α2-macroglobulin (α2-MG), secretory leucoprotease inhibitor (SLPI), and elafin; as well as two neutrophil activation markers (myeloperoxidase and lactoferrin) and three classic neutrophil activators [tumor necrosis factor-α (TNF-α), interleukin-8 (IL-8), and bacterial endotoxin]. Results: The levels of HNE, CG, and sElastin were elevated in the CAE group. The levels of α1-PI and α2-MG were also significantly increased in the CAE group. The levels of myeloperoxidase and lactoferrin were higher in the CAE group. The levels of TNF-α, IL-8, and endotoxin were unchanged in the CAE group compared with those in the CAD group. Conclusion: Neutrophils may participate in the process of vessel extracellular matrix destruction and coronary ectasia by releasing NSPs in a non-classical manner. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
15. Pharmacologic Management of Coronary Artery Ectasia
- Author
-
Sandrine Kakieu Djossi, Bandana Neupane, Anwar Khedr, Ekaterina Proskuriakova, Jihan A Mostafa, and Keji Jada
- Subjects
Acute coronary syndrome ,medicine.medical_specialty ,aspirin ,trimetazidine ,warfarin therapy ,coronary artery ectasia (cae) ,Trimetazidine ,Cardiology ,b-blockers ,statins ,Coronary artery disease ,Angina ,Internal medicine ,medicine ,Internal Medicine ,Thrombus ,Aspirin ,business.industry ,nitrates ,Coronary artery ectasia ,General Engineering ,aneurysmal coronary artery disease ,ca channel blockers ,medicine.disease ,ace inhibitors ,Coronary vasospasm ,business ,medicine.drug - Abstract
Coronary artery ectasia (CAE) is a rare form of aneurysmal coronary heart disease. It is defined as a dilatation of the coronary artery by more than one-third of its length and with a diameter 1.5 times of a normal coronary artery adjacent to it. This condition increases the risk of angina pectoris and acute coronary syndrome. Hence, we discuss the pharmacologic options for primary and secondary prevention of CAE complications. Antiplatelets such as aspirin are considered the mainstay of treatment in patients with CAE. Anticoagulants such as warfarin are warranted on a case-by-case basis to prevent thrombus formation depending on the presence of concomitant obstructive coronary artery disease and the patient's risk of bleeding. Since atherosclerosis is the most common cause of CAE, statins are indicated in all patients for primary prevention. Angiotensin-converting enzyme (ACE) inhibitors may be indicated, especially in hypertensive patients, due to their anti-inflammatory properties. Beta-blockers may be indicated due to their antihypertensive and anti-ischemic effects. Calcium (Ca) channel blockers may be needed to prevent coronary vasospasm. Nitrates are generally contraindicated as they may lead to worsening of symptoms. Other antianginal medications such as trimetazidine can improve exercise tolerance with no reported adverse events in these patients.
- Published
- 2021
16. Chronic active Epstein–Barr virus infection manifesting as coronary artery aneurysm and uveitis
- Author
-
Xiao, Haijuan, Hu, Bing, Luo, Rongmu, Hu, Huili, Zhang, Junmei, Kuang, Weiying, Zhang, Rui, Li, Li, and Liu, Gang
- Published
- 2020
- Full Text
- View/download PDF
17. Chronic active Epstein–Barr virus infection manifesting as coronary artery aneurysm and uveitis
- Author
-
Rongmu Luo, Li Li, Gang Liu, Weiying Kuang, Bing Hu, Rui Zhang, Junmei Zhang, Haijuan Xiao, and Huili Hu
- Subjects
Lymphoproliferative disorders (LPDs) ,0301 basic medicine ,Epstein-Barr Virus Infections ,Herpesvirus 4, Human ,medicine.medical_specialty ,Chronic active Epstein–Barr virus infection (CAEBV) ,Mononucleosis ,medicine.medical_treatment ,Hepatosplenomegaly ,Case Report ,Physical examination ,Hematopoietic stem cell transplantation ,Coronary artery aneurysm (CAA) ,030204 cardiovascular system & hematology ,Biology ,Antibodies, Viral ,Gastroenterology ,lcsh:Infectious and parasitic diseases ,Uveitis ,03 medical and health sciences ,0302 clinical medicine ,Blurred vision ,Virology ,Internal medicine ,medicine ,Humans ,lcsh:RC109-216 ,Medical history ,Vision, Ocular ,Coronary artery aneurysm ,medicine.diagnostic_test ,Coronary Aneurysm ,Prognosis ,medicine.disease ,Coronary artery ectasia (CAE) ,Treatment Outcome ,030104 developmental biology ,Infectious Diseases ,Child, Preschool ,Chronic Disease ,Hematopoietic stem cell transplantation (HSCT) ,Female ,medicine.symptom ,Tomography, X-Ray Computed - Abstract
Background Chronic active Epstein–Barr virus (CAEBV) infection is a type of lymphoproliferative disorder characterized by chronic or recurrent infectious mononucleosis (IM)-like symptoms, which can have less-frequent clinical presentations. The prognosis of CAEBV is poor, and hematopoietic stem cell transplantation (HSCT) has been shown to be the only potentially effective treatment. In this article, we present a special CAEBV case of a patient who had no typical IM-like symptoms at the early stage, but manifested with severe and progressive coronary artery aneurysm (CAA), abdominal aortic lesions, and severe uveitis. These manifestations were uncommon features and could only be blocked by HSCT. Case presentation A 4-year-old girl with no special medical history complained of decreased vision for 10 months and cough after physical activities for three months. The blurred vision grew rapidly worse within one month, until only light perception remained. She was diagnosed with uveitis and cataract, and received prednisone and ciclosporin A treatment. However, her vision did not improve. Physical examination showed slight hepatosplenomegaly. Ultrasonic cardiogram showed bilateral CAA (5.0 mm and 5.7 mm for inner diameters), and abdominal CT scan revealed a thickened aortic wall, as well as stenosis and dilation of the segmental abdominal aorta. Other significant findings were increased EBV-DNA (3.29 × 104 copies/mL) from peripheral blood, positive EBV antibodies (EBV-CA-IgG, EBV-EA-IgA, and EBV-NA-IgG), and positive EBV-encoded small RNAs found by bone marrow biopsy. Based on her clinical manifestations and evidence for EBV infection, we diagnosed CAEBV. She received allogeneic HSCT, and the cataract operation was performed after HSCT. EBV-DNA could not be detected in peripheral blood after HSCT. Her CAAs did not progress, and uveitis was well controlled. Her vision recovered gradually over the 3 years after HSCT. Conclusions We present a rare CAEBV case of a patient who suffered from uncommon and severe cardiovascular and ocular involvement that was relieved by HSCT. Therefore, early recognition and diagnosis of CAEBV are of vital importance to improve its prognosis. In summary, this atypical CAEBV case could help us recognize similar cases more easily, make the right diagnosis as early as possible, and deliver proper and timely treatment.
- Published
- 2020
- Full Text
- View/download PDF
18. Five-years' prognostic analysis for coronary artery ectasia patients with coronary atherosclerosis: A retrospective cohort study.
- Author
-
Liu R, Gao X, Liang S, and Zhao H
- Abstract
Background: Most of coronary artery ectasia (CAE) patients have comorbid coronary atherosclerosis. It was lack of prognostic data for CAE patients with coronary heart disease (CHD) and for whom with acute myocardial infarction (AMI)., Objective: To determine the overall prognosis for CAE patients., Materials and Methods: This study was a retrospective cohort study. Fifty-one patients with CAE and comorbid AMI (CAE + AMI) and 108 patients with CAE and comorbid CHD (CAE + CHD) were enrolled and matched to non-CAE subjects at a ratio of 1:3 using a propensity score method, respectively. Controls for CAE + AMI group were 153 AMI patients, controls for CAE group were 324 CHD patients and 329 participants with relatively normal coronary arteries (CON). We followed them up to observe major cardiovascular events (MACE)., Results: The Kaplan-Meier curves showed that the prognosis in CAE + AMI group was worse than in AMI group (5-year non-MACE rate: 62.70% vs. 79.70%, P = 0.010), the prognosis in CAE group was worse than in CHD and CON groups (5-year non-MACE rate: 74.10% vs. 85.80% and 96.70%, respectively, P = 0.000). The main MACEs in CAE + AMI and CAE groups were AMI reoccurrence (19.61% vs. 4.57%, P = 0.002) and re-hospitalization due to repeated angina pectoris (14.81% vs. 8.33% and 2.74%, P = 0.000), respectively. Additionally, the COX regression analysis revealed that the protective factors for preventing MACE in CAE + AMI group included antiplatelet agents (hazard ratio = 0.234, P = 0.016) and angiotensin-converting enzyme inhibitor/angiotensin receptor inhibitor (ACEI/ARB, hazard ratio = 0.317, P = 0.037). Whereas the main factor promoting MACE in CAE group was the degree of coronary stenosis (Gensini score, hazard ratio = 1.011, P = 0.022)., Conclusion: The prognosis of patients with CAE + AMI was worse than that of those with AMI. The overall prognosis of patients with CAE was worse than that of those with CHD. CAE + AMI and CAE groups had different characteristics; the former was prone to AMI reoccurrence, and the latter was prone to repeated angina pectoris. To prevent MACE, medications, including antiplatelets and ACEI/ARBs, are indicated for patients with CAE + AMI, whereas prevention of the progression of atherosclerotic lesions is indicated for patients with CAE., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewers WL and LZ declared a shared parent affiliation with several of the authors to the handling editor at the time of the review., (Copyright © 2022 Liu, Gao, Liang and Zhao.)
- Published
- 2022
- Full Text
- View/download PDF
19. Is Coronary Artery Ectasia a Progressive Disease? A Self-Controlled Retrospective Cohort Study.
- Author
-
Liu R, Zhao H, Gao X, and Liang S
- Abstract
Objective: It is essential to understand whether coronary artery ectasia (CAE) progresses over time because the patients might be under the risk of coronary rupture, and stent implant should be avoided if ectatic changes progress. Methods: A consecutive series of 99 CAE patients who had undergone coronary angiography at least twice were enrolled and followed up for 1-16 years until they received a second angiogram. Subjects were divided into two groups (1-5 vs. 5-16 years of follow-up), then the basic clinical characteristics and coronary artery images were compared over time. Results: (1) All CAE patients exhibited atherosclerosis, and a majority presented with acute myocardial infarction. Most baseline clinical characteristics were relatively stable. (2) Atherosclerosis (indicated by the distribution of stenosis in coronary vessels) and the Gensini scores progressed significantly. Ectasia extent showed minimal changes as indicated by blood vessel involvement, Markis type, coronary blood flow, ectasia diameter, and ectasia length. (3) Multilinear regression analysis revealed that the underlying factors related to stenosis evolution indicated by fold of Gensini score were: longer time interval, lower baseline Gensini score, and higher hypersensitive C-reactive protein concentration. (4) There was a relationship between the ectatic diameter and the extent of stenosis. Conclusions: For CAE patients with atherosclerosis followed for 1-16 years, there was minimal CAE progression, while the atherosclerosis progressed and the ectasia extent was related to degree of stenosis. The results indicate that prevention and treatment of atherosclerotic changes might have more clinical significance than addressing ectatic changes., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Liu, Zhao, Gao and Liang.)
- Published
- 2021
- Full Text
- View/download PDF
20. Pharmacologic Management of Coronary Artery Ectasia.
- Author
-
Khedr A, Neupane B, Proskuriakova E, Jada K, Kakieu Djossi S, and Mostafa JA
- Abstract
Coronary artery ectasia (CAE) is a rare form of aneurysmal coronary heart disease. It is defined as a dilatation of the coronary artery by more than one-third of its length and with a diameter 1.5 times of a normal coronary artery adjacent to it. This condition increases the risk of angina pectoris and acute coronary syndrome. Hence, we discuss the pharmacologic options for primary and secondary prevention of CAE complications. Antiplatelets such as aspirin are considered the mainstay of treatment in patients with CAE. Anticoagulants such as warfarin are warranted on a case-by-case basis to prevent thrombus formation depending on the presence of concomitant obstructive coronary artery disease and the patient's risk of bleeding. Since atherosclerosis is the most common cause of CAE, statins are indicated in all patients for primary prevention. Angiotensin-converting enzyme (ACE) inhibitors may be indicated, especially in hypertensive patients, due to their anti-inflammatory properties. Beta-blockers may be indicated due to their antihypertensive and anti-ischemic effects. Calcium (Ca) channel blockers may be needed to prevent coronary vasospasm. Nitrates are generally contraindicated as they may lead to worsening of symptoms. Other antianginal medications such as trimetazidine can improve exercise tolerance with no reported adverse events in these patients., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2021, Khedr et al.)
- Published
- 2021
- Full Text
- View/download PDF
21. Multi-Vessel Coronary Artery Ectasia.
- Author
-
Madkour M and Hu P
- Abstract
Coronary artery ectasia is a relatively rare entity, especially when it involves the left main coronary artery. Furthermore, it is even more uncommon for such a disease process to involve multiple coronary arteries. Here we describe a case of a 78-year-old female who did not possess any of the common risk factors or vasculitic etiologies associated with coronary artery ectasia, who was found to have multi-vessel ectatic segments, including that of the left main coronary artery. This case illuminates the difficult decision making regarding stenting of the coronary arteries with ectatic segments and the decision to anticoagulate., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2021, Madkour et al.)
- Published
- 2021
- Full Text
- View/download PDF
22. Difference in inflammation, atherosclerosis, and platelet activation between coronary artery aneurysm and coronary artery ectasia.
- Author
-
Wei W, Wang X, Huang Z, Li X, and Luo Y
- Abstract
Background: Coronary artery aneurysm (CAA) and coronary artery ectasia (CAE) may be two different types of coronary artery dilatation with unknown etiology. This study aimed to compare the differences between CAA and CAE and to investigate their pathogenesis and the necessity of antiplatelet therapy., Methods: One hundred patients each with confirmed CAA, CAE, and normal coronary artery (NCA) from September 2017 to July 2019 were included. All patients completed examinations of the ankle-brachial index (ABI), pulse wave rate, and carotid ultrasonography; and were tested for routine blood, lipid, and immune parameters. Blood samples were collected 1 week after the withdrawal of antiplatelet drugs, and vascular inflammatory indexes, platelet activation indexes, thromboelastography, and the platelet aggregation rate were measured. Analysis of variance and the chi-square or Fisher exact test were used for statistical analysis., Results: The perinuclear anti-neutrophil cytoplasmic antibody (ANCA), endothelial-1, matrix metalloproteinase-9, and tumor necrosis factor-α were significantly higher in CAE than in NCA, while cytoplasmic ANCA was appreciably higher in CAE than in CAA (P<0.05). Myeloperoxidase and growth/differentiation factor-15 were significantly higher in CAE than in CAA and NCA (P<0.05). ABI was significantly lower in CAA and CAE than in NCA (P<0.05), low-density lipoprotein/high-density lipoprotein was significantly higher in CAA than in NCA (P<0.05), and the detection rate of carotid artery thickening was significantly higher in CAA than in CAE and NCA (P<0.05). The Gensini and SYNTAX scores were significantly higher in CAA than in CAE (P<0.05). The percentages of CD62P and PAC-1 were higher in CAA and CAE than in NCA (P<0.05). The arachidonic acid aggregation rate in CAA and adenosine 5'-diphosphate aggregation rate in CAE were significantly higher than in NCA (P<0.05). The values of thrombin formation time and reaction time were significantly lower in CAE than in NCA (P<0.05), and the α angle was significantly higher in CAE than in NCA., Conclusions: CAE was closely related to inflammation, whereas CAA was closely related to atherosclerosis. Platelet activation was present in both diseases; therefore, antiplatelet therapy is recommended., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd-20-1579). The authors have no conflicts of interest to declare., (2020 Journal of Thoracic Disease. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
23. Neutrophil serine proteases and their endogenous inhibitors in coronary artery ectasia patients
- Author
-
Shuyang Zhang, Hou-Zao Chen, Lianfeng Chen, Ruifeng Liu, and Wei Wu
- Subjects
Male ,medicine.medical_specialty ,Cathepsin G ,Neutrophils ,neutrophil serine proteases (NSPs) ,Coronary Artery Disease ,soluble elastin (sElastin) ,chemistry.chemical_compound ,coronary artery ectasia (CAE) ,Proteinase 3 ,Internal medicine ,medicine ,Humans ,Original Investigation ,biology ,business.industry ,Fibrinolysis ,Coronary artery ectasia ,Elastase ,Proteolytic enzymes ,Middle Aged ,extracellular matrix (ECM) ,medicine.disease ,Elastin ,Cross-Sectional Studies ,Endocrinology ,chemistry ,Case-Control Studies ,Myeloperoxidase ,Immunology ,human neutrophil elastase (HNE) ,biology.protein ,Female ,Serine Proteases ,Leukocyte Elastase ,Cardiology and Cardiovascular Medicine ,business ,Elafin ,Dilatation, Pathologic ,SLPI - Abstract
Objective: Proteolytic enzymes possibly contribute to coronary artery ectasia (CAE). This study aimed to determine whether neutrophils, neutrophil serine proteases (NSPs), and their endogenous inhibitors participated in the pathological process of CAE. Methods: The study consisted of 30 patients with CAE, 30 patients with coronary artery disease (CAD), and 29 subjects with normal coronary arteries (Control). The following circulating items were measured: the main NSPs, including human neutrophil elastase (HNE), cathepsin G (CG), and proteinase 3 (PR3); soluble elastin (sElastin), which was a degradation product of elastin fibres; NSP inhibitors such as α1-protease inhibitor (α1-PI), α2-macroglobulin (α2-MG), secretory leucoprotease inhibitor (SLPI), and elafin; as well as two neutrophil activation markers (myeloperoxidase and lactoferrin) and three classic neutrophil activators [tumor necrosis factor-α (TNF-α), interleukin-8 (IL-8), and bacterial endotoxin]. Results: The levels of HNE, CG, and sElastin were elevated in the CAE group. The levels of α1-PI and α2-MG were also significantly increased in the CAE group. The levels of myeloperoxidase and lactoferrin were higher in the CAE group. The levels of TNF-α, IL-8, and endotoxin were unchanged in the CAE group compared with those in the CAD group. Conclusion: Neutrophils may participate in the process of vessel extracellular matrix destruction and coronary ectasia by releasing NSPs in a non-classical manner. (Anatol J Cardiol 2015; 15(0): 000-000)
- Published
- 2015
- Full Text
- View/download PDF
24. Transcriptional expression profiles of the main proteinases and their regulators in coronary artery ectasia patients' mononuclear cells.
- Author
-
Liu R, Wu W, Chen L, Chen H, and Zhang S
- Subjects
- Aged, Coronary Angiography methods, Dilatation, Pathologic blood, Dilatation, Pathologic diagnosis, Dilatation, Pathologic enzymology, Female, Growth Differentiation Factor 15 metabolism, Humans, Interferon-gamma metabolism, Interleukin-1alpha metabolism, Male, Matrix Metalloproteinase 1 metabolism, Matrix Metalloproteinase 9 metabolism, Middle Aged, Transcriptome, Coronary Artery Disease blood, Coronary Artery Disease diagnosis, Coronary Artery Disease enzymology, Coronary Vessels pathology, Leukocytes, Mononuclear enzymology
- Abstract
Objective: Proteolytic enzymes might contribute to coronary artery ectasia (CAE) through the destruction of extracellular matrix (ECM) vessel components. This study aimed to find out if peripheral blood mononuclear cells (PBMCs) served as a source of those proteinases and their regulators., Method: In this study, transcriptional expression profiles of the main proteinases and their regulators were detected in the PBMCs of CAE patients as follows: (1) matrix metalloproteinases (MMP) 1, 2, 3, 8, 9, 10, 12 and 13; (2) the serine proteinases elastase: cathepsin G and proteinases 3; (3) the cysteine proteinases: cathepsin L and cathepsin S; (4) the main endogenous inhibitors for the above proteinases: tissue inhibitors of metalloproteinase (TIMP) 1 and 2, α1-antitrypsin (α1-PI) and α2-macroglobulin (A2M); (5) twelve cytokines that could regulate the above proteinases., Result: The characteristic changes in CAE were: (1) MMP1 and MMP9 increased while the serine and cysteine families did not change; (2) the four proteinase inhibitors did not change in the CAE group; (3) among the 12 cytokines, interleukin-1 alpha (IL1A), platelet-derived growth factor (PDGF), interferon gamma (IFNγ) and growth differentiation factor 15 (GDF15) were elevated. Partial correlation analysis showed that MMP1 significantly correlated with IL1A and with IFNγ, and MMP9 correlated with IFNγ and with GDF 15., Conclusion: PBMCs might participate in the pathological process of CAE by the increased expression of MMP1, MMP9, IL1A, IFNγ and GDF15.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.